Trial Profile

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of HH2853 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphomas or Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HH 2853 (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sarcoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Haihe Biopharma

Most Recent Events

07 May 2024 Planned number of patients changed from 168 to 254.
07 May 2024 Status changed from recruiting to completed.
12 Mar 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com